During the corresponding time, Prosomnus Inc recorded a revenue increase by 34.44 % year on year, sequentially revenue grew by 21.91 %. While revenue at the Prosomnus Inc 's corporate clients
Prosomnus Inc's Comment on Sales, Marketing and Customers
In 2023, the company achieved a 96% retention rate among its top 100 customers, primarily sleep dentists, and experienced a 33% revenue increase from this group. Its largest customer accounts for approximately 4.4% of total revenues. The company serves a provider network across the United States, including therapy providers, physicians practicing sleep medicine, integrated health systems, and hospital networks. Its ProSomnus precision intraoral devices are reimbursable by major commercial medical payors such as United Healthcare, Medicare, and social health insurance programs in various countries. United Healthcare updated its medical policy (#2024T0525NN) to recognize oral appliance therapy as a prerequisite for Implantable Hypoglossal Nerve Stimulation. The company plans to expand its North American direct sales organization and pursue international growth to increase case volume and market presence in sleep medicine.
Prosomnus Inc’s Comment on Sales, Marketing and Customers
In 2023, the company achieved a 96% retention rate among its top 100 customers, primarily sleep dentists, and experienced a 33% revenue increase from this group. Its largest customer accounts for approximately 4.4% of total revenues. The company serves a provider network across the United States, including therapy providers, physicians practicing sleep medicine, integrated health systems, and hospital networks. Its ProSomnus precision intraoral devices are reimbursable by major commercial medical payors such as United Healthcare, Medicare, and social health insurance programs in various countries. United Healthcare updated its medical policy (#2024T0525NN) to recognize oral appliance therapy as a prerequisite for Implantable Hypoglossal Nerve Stimulation. The company plans to expand its North American direct sales organization and pursue international growth to increase case volume and market presence in sleep medicine.
Sources:
Prosomnus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Prosomnus Inc’s corporate clients.
For your research, we’ve provided 9 tables on Prosomnus Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
